Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Growth in Short Interest

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 1,810,000 shares, an increase of 145.8% from the January 15th total of 736,500 shares. Currently, 9.4% of the shares of the stock are short sold. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is presently 1.8 days.

Hedge Funds Weigh In On Vigil Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in VIGL. Blair William & Co. IL bought a new position in Vigil Neuroscience during the 4th quarter worth approximately $551,000. abrdn plc raised its stake in Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock worth $898,000 after buying an additional 293,461 shares during the last quarter. Verition Fund Management LLC acquired a new position in Vigil Neuroscience in the third quarter valued at $442,000. Point72 Asset Management L.P. boosted its position in Vigil Neuroscience by 7.7% during the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock valued at $5,440,000 after acquiring an additional 115,000 shares during the last quarter. Finally, Walleye Capital LLC grew its holdings in Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after acquiring an additional 92,217 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Vigil Neuroscience Stock Up 1.5 %

Shares of NASDAQ:VIGL opened at $2.69 on Thursday. The firm has a market cap of $109.97 million, a P/E ratio of -1.31 and a beta of 1.84. The business has a fifty day simple moving average of $2.04 and a 200 day simple moving average of $2.95. Vigil Neuroscience has a 12-month low of $1.49 and a 12-month high of $6.06.

Analyst Ratings Changes

A number of equities analysts recently issued reports on VIGL shares. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Wedbush increased their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. William Blair assumed coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a report on Thursday, January 23rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $19.75.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.